JOHNSON & JOHNSON ANNOUNCES NEW PHASE 2 NIPOCALIMAB STUDY DATA IN SJÖGREN'S DISEASE THAT REVEAL INSIGHTS ON IMPORTANCE OF SYMPTOM IMPROVEMENTS MOST VALUED BY PATIENTS

Reuters · 1d ago

Please log in to view news